- Home
- GRO vs NPCE Comparison
GRO vs NPCE Comparison
Compare GRO & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRO
- NPCE
- Stock Information
- Founded
- GRO 2006
- NPCE 1997
- Country
- GRO Canada
- NPCE United States
- Employees
- GRO N/A
- NPCE N/A
- Industry
- GRO
- NPCE Medical Specialities
- Sector
- GRO
- NPCE Health Care
- Exchange
- GRO NYSE
- NPCE Nasdaq
- Market Cap
- GRO 371.9M
- NPCE 336.7M
- IPO Year
- GRO 2024
- NPCE 2021
- Fundamental
- Price
- GRO $9.05
- NPCE $10.64
- Analyst Decision
- GRO
- NPCE Buy
- Analyst Count
- GRO 0
- NPCE 7
- Target Price
- GRO N/A
- NPCE $15.29
- AVG Volume (30 Days)
- GRO 36.2K
- NPCE 67.6K
- Earning Date
- GRO 02-03-2025
- NPCE 11-12-2024
- Dividend Yield
- GRO N/A
- NPCE N/A
- EPS Growth
- GRO N/A
- NPCE N/A
- EPS
- GRO N/A
- NPCE N/A
- Revenue
- GRO N/A
- NPCE $76,452,000.00
- Revenue This Year
- GRO N/A
- NPCE $23.46
- Revenue Next Year
- GRO N/A
- NPCE $15.49
- P/E Ratio
- GRO N/A
- NPCE N/A
- Revenue Growth
- GRO N/A
- NPCE 27.00
- 52 Week Low
- GRO $8.55
- NPCE $5.45
- 52 Week High
- GRO $15.00
- NPCE $18.15
- Technical
- Relative Strength Index (RSI)
- GRO N/A
- NPCE 54.53
- Support Level
- GRO N/A
- NPCE $10.00
- Resistance Level
- GRO N/A
- NPCE $12.41
- Average True Range (ATR)
- GRO 0.00
- NPCE 1.04
- MACD
- GRO 0.00
- NPCE -0.14
- Stochastic Oscillator
- GRO 0.00
- NPCE 28.67
About GRO BRAZIL POTASH CORP
Brazil Potash Corp is a mineral exploration and development company with a potash mining project located in the state of Amazonas, Brazil. The company's technical operations are based in Autazes, Amazonas, Brazil, and Belo Horizonte, Minas Gerais, Brazil. The operating activities of the company includes focusing on the extraction and processing of potash ore from underground mine and selling and distributing the processed potash in Brazil.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.